<DOC>
	<DOCNO>NCT01103362</DOCNO>
	<brief_summary>To generate additional long-term safety efficacy data flibanserin premenopausal woman establish long-term safety tolerability flibanserin naturally postmenopausal woman Hypoactive Sexual Desire Disorder complete prior clinical trial flibanserin ( Trial 511.130 , 511.147 , 511.156 ) .</brief_summary>
	<brief_title>A 28-week Safety Study Flibanserin Pre- Postmenopausal Women With Hypoactive Sexual Desire Disorder</brief_title>
	<detailed_description />
	<mesh_term>Sexual Dysfunctions , Psychological</mesh_term>
	<criteria>Inclusion criterion : 1 . Women primary diagnosis Hypoactive Sexual Desire Disorder ( HSDD ) complete prior trial flibanserin . Such completion require compliance trial medication trial visit schedule include posttreatment visit require clinical trial . Early discontinuation reason disqualifies patient entry trial . Patients must enroll study within 7 day complete final visit parent trial . 2 . The premenopausal patient must use medically acceptable method contraception least two month baseline continue use medically acceptable method contraception trial . 3 . Postmenopausal patient must naturally postmenopausal woman age least one ovary . Natural menopause define great 12 month spontaneous amenorrhea . 4 . In investigator 's opinion , patient must willing adhere trial requirement well able perform . 5 . Patients must able willing give meaningful , write informed consent prior participation trial , accordance regulatory requirement . Patients must sufficient understand communicate effectively investigator , willing discus sexual functioning study staff . Exclusion criterion : 1 . Patients history Major Depressive Disorder ( MDD ) within six month prior Screen Visit , score great equal 14 Beck Depression Inventory II ( BDIII ) , history suicidal behavior suicidal ideation accord ColumbiaSuicide Severity Rating Scale ( CSSRS® ) . If psychiatrist psychologist , use clinical judgment , believe patient score 14 19 BDI®II depress , patient may enter trial . NOTE : If patient report positive response BDI®II Question 9 and/or Yes response either CSSRS® Suicide Ideation section Question 1 and/or 2 and/or question Suicide Behavior section , please refer Section 5.2.5 immediate action require . 2 . At Screen Visit , serum alanine aminotransferase , serum aspartate aminotransferase , alkaline phosphatase , total bilirubin great equal three time upper limit normal ; blood urea nitrogen great equal 30 mg/deciliter ( dL ) , plasma creatinine great equal 2 mg/dL , hemoglobin &lt; 9.5 grams/dL , leukopenia ( &lt; 2.5 x 103/microliter [ µL ] ) , neutropenia ( &lt; 1.5 x 103/µL ) , lymphopenia ( &lt; 0.8 x 103/µL ) , thrombocytopenia ( &lt; 100 x 103/µL ) thrombocytosis ( &gt; 500 x 103/µL ) ; random glucose &gt; upper limit normal . 3 . Patients newly develop , selfreported symptoms End Treatment parent trial visit trial Screen Visit pelvic inflammatory disease , urinary tract vaginal infection / vaginitis , cervicitis , interstitial cystitis , vulvodynia , significant vaginal atrophy . 4 . Patients history cancer within last ten year , noninvasive , previously resect basal cell carcinoma skin . 5 . Patients whose sexual function affect hysterectomy , oophorectomy , pelvic vaginal surgery . 6 . Patients pregnant ( urine pregnancy test Screen Visit ) pregnant within month prior Screen Visit breastfeed breastfed within last six month prior Baseline Visit . 7 . Patients receive medication exclude prior safety efficacy trial flibanserin cause sexual dysfunction safetyrelevant interaction ( i.e. , antidepressant , anxiolytic , antipsychotic , anticonvulsant , anticoagulant ) . 8 . Patients clinically relevant condition might interfere ability participate trial . 9 . Participation trial investigational medication flibanserin within one month prior Screen Visit .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>